AMLX Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Halper Sadeh LLP

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

15 days ago - By: The Motley Fool - Mentions: ABVX CGON COGT CNTA

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead

15 days ago - By: The Motley Fool - Mentions: LQDA ABVX CGON COGT ...

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch

a month ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

3 months ago - By: Stocktwits

Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder

4 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

19 days ago - By: The Rosen Law Firm, P.A.

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

21 days ago - By: Rosen Law Firm

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

22 days ago - By: Zacks Investment Research - Mentions: EXAS

Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?

26 days ago - By: Grabar Law Office - Mentions: AVTR HUM MSS

Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf

a month ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

a month ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

a month ago - By: Grabar Law Office - Mentions: FIVE HUM TMCI

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TMCI): Grabar Law Office Investigates Claims on Your Behalf

a month ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

a month ago - By: Halper Sadeh LLC

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

a month ago - By: Zacks Investment Research

What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now?

a month ago - By: Grabar Law Office - Mentions: BAX HUM FIVE

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office Investigates Claims on Your Behalf

a month ago - By: Kuehn Law, PLLC

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

a month ago - By: Grabar Law Office - Mentions: BAX FIVE HUM

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office is Investigating Claims on Your Behalf

2 months ago - By: Grabar Law Office - Mentions: HUM FIVE HTZ

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

2 months ago - By: Bragar Eagel & Squire

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders

2 months ago - By: Grabar Law Office - Mentions: HUM FIVE TMCI

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

2 months ago - By: Grabar Law Office - Mentions: FIVE HUM TMCI

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

2 months ago - By: Grabar Law Office - Mentions: HUM FIVE VSTS

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

2 months ago - By: Grabar Law Office - Mentions: VSTS HUM UNCY

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

2 months ago - By: Kuehn Law, PLLC

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

3 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

3 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

3 months ago - By: Stocktwits - Mentions: IWMW VTWG BAC

US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target

3 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

3 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

4 months ago - By: Amylyx Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

4 months ago - By: Amylyx Pharmaceuticals, Inc.

AMYLYX PHARMACEUTICALS INC (AMLX) Stock News

AMLX Latest News, Press Relases and Analysis

HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

This Biotech Fund Has an $85 Million Bet on Amylyx as Stock Surges 180% and Co-CEOs Tease 'Transformational' Year Ahead

This Biotech Fund Made a New $40 Million Bet on Liquidia Amid Blockbuster Commercial Drug Launch

Earnings Scheduled For November 6, 2025

Amylyx Discontinues Investigative Therapy Program In Rare Neurological Disorder

Earnings Scheduled For August 7, 2025

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLX

Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year?

Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Avantor, Inc. (NYSE: AVTR); Humana Inc. (NYSE: HUM); and Maison Solutions Inc. (NASDAQ: MSS): Grabar Law Office Investigates Claims on Your Behalf

Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results

Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Five Below, Inc. (NASDAQ: FIVE); Humana Inc. (NYSE: HUM); and Treace Medical Concepts (NASDAQ: TMCI): Grabar Law Office Investigates Claims on Your Behalf

Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights

What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now?

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office Investigates Claims on Your Behalf

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Baxter International Inc. (NYSE: BAX); Five Below, Inc. (NASDAQ: FIVE); and Humana Inc. (NYSE: HUM): Grabar Law Office is Investigating Claims on Your Behalf

Important Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Hertz Global Holdings, Inc. (NASDAQ: HTZ): Grabar Law Office is Investigating Claims on Your Behalf

AMYLYX INVESTIGATION: Bragar Eagel & Squire, P.C. Urges Amylyx Investors to Contact the Firm Regarding Ongoing Investigation into Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Treace Medical Concepts, Inc. (NASDAQ: TMCI): Grabar Law Office is Investigating Claims on Your Behalf

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Five Below, Inc. (NASDAQ: FIVE); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

Attention Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX); Humana Inc. (NYSE: HUM); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and Vestis Corp. (NYSE: VSTS): Grabar Law Office is Investigating Claims on Your Behalf

Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm

Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock

Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock

US FDA Withdraws Approval For Amylyx’s Neurodegenerative Disorder Drug, But BofA Hikes Price Target

Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP)

Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences

Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results

Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025